Drug Database
Back to search

Belgium· BE-AMP-SAM662071-00

Finlee 10 mg

A dabrafenib product containing dabrafenib mesilate, registered in Belgium by Novartis Europharm. The same ATC class is registered in 14 of our 19 countries.

ATC L01EC02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedFinlee 10 mgATCL01EC02REGISTER NO.BE-AMP-SAM662071-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dabrafenib mesilateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dabrafenib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EC02 (dabrafenib), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search dabrafenib products by name

Dabrafenib · ATC L01EC02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dabrafenib costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Dabrafenib · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$232.39
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Dabrafenib Mesilate
Manufacturer
Novartis Europharm
Country
Belgium (BE)
ATC code
L01EC02
ATC class
Dabrafenib
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    7746332
  • be_apb
    4769378

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

522 interactions on record for dabrafenib.

Graded by severity as the source publishes them — 79 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dabrafenib against other medicinesHow interaction checks work

Dabrafenib · interactions on record

522 records

  • 79 severe
  • 430 moderate
  • 13 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • AvatrombopagB02BX08severe
  • VoxelotorB06AX03severe
  • RanolazineC01EB18severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dabrafenib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dabrafenib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Finlee, Tafinlar
  • Liechtenstein · Finlee, Tafinlar
  • Norway · Finlee, Tafinlar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6bf18449-1d47-4d22-82f0-89b4914ee8d1
GET /v1/drugs/6bf18449-1d47-4d22-82f0-89b4914ee8d1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispersible tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Finlee 10 mg",
  "name_fr": "Finlee 10 mg",
  "name_nl": "Finlee 10 mg",
  "amp_code": "SAM662071-00",
  "strengths": [
    "10.0000",
    "10.0000",
    "0.0008",
    "0.0008"
  ],
  "pack_count": 2,
  "substances": [
    "Dabrafenib Mesilate",
    "Dabrafenib",
    "Benzyl Alcohol",
    "Mannitol",
    "Propylene Glycol",
    "Acesulfame Potassium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Dabrafenib",
  "authorisation_numbers": [
    "EU/1/23/1767/002",
    "EU/1/23/1767/001"
  ]
}
API referenceMCP serverPlans

See everything about dabrafenib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console